ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2022
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/23/2026
Go back to ResMed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2022
August 15, 2022 6:31 AM EDT
CLSA analyst Andrew Paine downgraded ResMed (RMD:AU) (NYSE: RMD) from Buy (1) to Outperform (2) with a price target of AUD38.40.
The analyst comments "ResMed (RMD) delivered another solid result in 4Q22, with revenues (ex-Covid at pcp) +10% CC to US$914.7m. This was in-line... More
August 12, 2022 9:38 AM EDT
JPMorgan analyst David Low downgraded ResMed (NYSE: RMD) from Overweight to Neutral with a price target of $250.00 (from $255.00).
The analyst comments "ResMed is poised to take more market share over coming quarters as its device production ramps up and the key... More
August 11, 2022 4:08 PM EDT
ResMed (NYSE: RMD) reported Q4 EPS of $1.49, $0.04 better than the analyst estimate of $1.45. Revenue for the quarter came in at $914.7 million versus the consensus estimate of $910.54 million.
For earnings history and earnings-related data on ResMed (RMD) click here.
...
More
